Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Clinical trial NCT07436741 · RECRUITING

Trial details

NCT number: NCT07436741
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Pancreatic Cancer, Adult

Start date: 2026-03-03
Primary completion: 2028-09-01
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.